SEEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SEEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Seelos Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-2.86.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 29.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 47.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 50.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Seelos Therapeutics was 74.10% per year. The lowest was 5.80% per year. And the median was 34.50% per year.
For the Biotechnology subindustry, Seelos Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Seelos Therapeutics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Seelos Therapeutics (NAS:SEEL) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Thank you for viewing the detailed overview of Seelos Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Raj Mehra | director, officer: See Remarks | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Michael Joseph Golembiewski | officer: Chief Financial Officer | 7 TURTLE CT, FLEMINGTON NJ 08822 |
Daniel J. O'connor | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Margaret Dalesandro | director | ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
Judith Dunn | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Brian Lian | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Robin L Smith | director | C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747 |
Neil Morton | officer: SVP, Chief Business Officer | C/O APRICUS BIOSCIENCES, INC., 11975 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Richard W Pascoe | director, officer: CEO & Secretary | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital Master Fund Ltd. | 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Alexander J Denner | 10 percent owner | C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Sarissa Capital Management Lp | 10 percent owner | 660 STEAMBOAT ROAD, GREENWICH CT 06830 |
Sarissa Capital Domestic Fund Lp | 10 percent owner | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
From GuruFocus
By PRNewswire PRNewswire • 03-29-2023
By PRNewswire PRNewswire • 12-22-2022
By PRNewswire • 12-01-2023
By PRNewswire • 08-14-2023
By PRNewswire PRNewswire • 12-08-2022
By PRNewswire • 01-02-2024
By PRNewswire PRNewswire • 05-15-2023
By PRNewswire PRNewswire • 11-07-2022
By PRNewswire • 09-20-2023
By PRNewswire PRNewswire • 05-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.